Kamada (NASDAQ:KMDA) Stock Price Breaks Below Two Hundred Day Moving Average – What’s Next?

Kamada Ltd. (NASDAQ:KMDA) shares passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $7.82 and traded as low as $7.68. Kamada shares last traded at $7.77, with a volume of 88,202 shares.

Analyst Upgrades and Downgrades

Several research firms have weighed in on KMDA. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Wall Street Zen raised shares of Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 15th. William Blair set a $15.00 price objective on Kamada in a research report on Tuesday, July 21st. Weiss Ratings upgraded Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 9th. Finally, UBS Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Kamada in a research report on Friday, September 18th. Four investment analysts have rated the stock with a Buy rating. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $13.50.

Kamada Stock Up 0.5%

The business’s fifty day simple moving average is $8.20 and its two-hundred day simple moving average is $7.82. The company has a market cap of $446.81 million, a price-to-earnings ratio of 20.45, a PEG ratio of 0.65 and a beta of 0.89.

Kamada (NASDAQ:KMDA) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. The business had revenue of $54.92 million during the quarter, compared to analysts’ expectations of $50.84 million. Kamada had a net margin of 11.60% and a return on equity of 8.37%. Sell-side analysts predict that Kamada Ltd. will post 0.48 EPS for the current fiscal year.

Kamada Cuts Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, September 17th. Investors of record on Thursday, August 27th were given a $0.17 dividend. This is a negative change from Kamada’s previous annual dividend of $0.25. The ex-dividend date was Thursday, August 27th. This represents a yield of 206.0%. Kamada’s payout ratio is currently 31.58%.

Institutional Trading of Kamada

A hedge fund recently raised its position in Kamada stock. Aristides Capital LLC boosted its stake in Kamada Ltd. (NASDAQ:KMDA) by 4.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,491 shares of the biotechnology company’s stock after acquiring an additional 1,476 shares during the period. Aristides Capital LLC owned 0.06% of Kamada worth $288,000 as of its most recent SEC filing. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.